LUNG DRUG DELIVERY WITH CARBON DIOXIDE AEROSOL INHALERS

描述（改编自研究者摘要）：氯氟烃 (CFC)目前用于肺部疾病的定量吸入器中的推进剂 由于其高臭氧消耗潜力，药物输送正在逐步淘汰。 一个国际制药业财团建议， 零臭氧消耗潜能的氢氟烷烃（HFA）推进剂将取代 计量吸入器中的氟氯化碳。然而，仍然有一些关键的原因需要找到， 其他药物雾化替代品。HFA的潜在问题 推进剂包括毒性、与器械的不相容性、 与FDA批准的吸入器表面活性剂和降低的生物利用度的一些 毒品研究人员已经为一种肺部气雾剂的方法申请了专利 使用超临界流体二氧化碳作为 吸入器推进剂，并已证明其在体内的潜在用途， 一些实验室研究。研究人员设计了一些吸入器 使用二氧化碳作为推进剂的原型，并正在寻求资金， 这些设备的额外研究和开发。该技术具有 几个优点，包括零臭氧消耗潜力推进剂，低 二氧化碳的毒性，以及向肺部施用的能力， 亲脂性药物目前不能通过任何其他方法递送。的 研究人员建议改进并彻底测试一种新的定量形式， 使用二氧化碳作为推进剂的吸入器。 拟定商业应用： 1.这种臭氧友好型技术可能取代现有的MDI推进剂。 2.抗生素的气雾剂递送可以减少肺炎的死亡。 3.这种吸入器可能被证明比针头注射胰岛素更好。 4.这是一个很好的表面活性剂输送系统，以减少急性肺损伤。 5.这可以递送不能通过任何其他方法施用的药物。

DESCRIPTION (Adapted from the Investigator's Abstract): The chlorofluorocarbon (CFC) propellants currently being used in metered dose inhalers for pulmonary drug delivery are being phased out due to their high ozone depletion potential. An international pharmaceutical industry consortium has proposed that the zero-ozone depletion potential hydrofluoroalkane (HFA) propellants will replace CFCs in metered dose inhalers. There remain, however, crucial reasons to find other drug aerosolization alternatives. Potential problems with the HFA propellants include toxicity, incompatibility with devices, incompatibility with FDA approved inhaler surfactants and reduced bioavailability of some drugs. The investigators have patented a method for the pulmonary aerosol delivery of pharmaceuticals using supercritical fluid carbon dioxide as an inhaler propellant, and have demonstrated its potential usefulness in vivo in several laboratory studies. The investigators have designed a number of inhaler prototypes that use carbon dioxide as a propellant and are seeking funding for additional research and development of these devices. This technology has several advantages including zero-ozone depletion potential propellant, low toxicity of carbon dioxide, and the ability to administer to the lungs lipophilic drugs which cannot currently be delivered by any other method. The investigators propose to improve and thoroughly test a new form of metered dose inhaler which uses carbon dioxide as a propellant. PROPOSED COMMERCIAL APPLICATION: 1. This ozone-friendly technology may replace existing MDI propellants. 2. Aerosol delivery of antibiotics may reduce death from pneumonia. 3. This inhaler may prove to be better than needle injection of insulin. 4. This is an excellent surfactant delivery system to reduce acute lung injury. 5. This may deliver drugs that cannot be administered by any other method.